ArticleMolecular cancer therapeutics2011

Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.

Esther P Jane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.